Vanda Pharmaceuticals (NASDAQ:VNDA) and AnaptysBio (NASDAQ: ANAB) have announced an exclusive global licencing agreement granting Vanda the rights to commercialize imsidolimab, a treatment for generalized pustular psoriasis (GPP), in the U.S. and EU.
Under the terms of the agreement, Anaptys will receive $15 million from Vanda, comprising a $10 million upfront payment and $5 million for the existing drug supply. Additionally, Anaptys will earn a 10% royalty on global net sales of imsidolimab.
Imsidolimab has successfully completed two global Phase 3 studies in GPP.
Mihael H. Polymeropoulos, MD, president, CEO, and chairman of Vanda, stated, “We are excited to add imsidolimab to Vanda’s product portfolio for rare orphan disorders, as well as explore the potential of this IL-36 signal regulator in the treatment of additional inflammatory conditions where the IL-36 homeostatic balance is dysregulated.”
“Imsidolimab has great synergy with our commercial portfolio, leveraging both our rare disease expertise in the US and EU as well as the anti-inflammatory portfolio that includes Ponvory for multiple sclerosis, psoriasis and ulcerative colitis,” Dr. Polymeropoulos added.
Daniel Faga, president and CEO of Anaptys, commented, “Vanda is an ideal partner for imsidolimab due to their strong regulatory and commercial capabilities in the US and Europe, evidenced by successful recent launches in specialty and rare diseases, and their commitment to invest in label expansion across their therapeutic portfolio, including their growing presence in inflammatory disease.”
Mr. Faga continued, “Following our productive pre-BLA meeting with FDA in 2024, we look forward to Vanda’s BLA and MAA submissions later in 2025, with the hope that this potentially differentiated therapeutic option will be made available for patients living with GPP, a burdensome, and sometimes life-threatening skin disease.”
